| Cat.No. | Name | Information |
|---|---|---|
| M1861 | Silmitasertib (CX-4945) | CX-4945 (Silmitasertib) is a potent small molecule protein kinase inhibitor that selectively binds to and inhibits the enzyme casein kinase II (CK2). |
| M10105 | PF670462 dihydrochloride | PF670462 is a potent and selective inhibitor of of CK1 delta and epsilon (CK1δ/ε). |
| M8957 | LH846 | LH846 is a selective inhibitor of casein kinase with IC50 values of 290 nM, 1.3 μM and 2.5 μM for CK1δ, ε and α, respectively. |
| M8903 | SR-3029 | SR-3029 is a potent and ATP competitive CK1δ and CK1ε inhibitor, with IC50s of 44 nM and 260 nM, respectively. |
| M8775 | DMAT | DMAT (Ck2 Inhibitor II) is a high affinity ATP-competitive inhibitor of casein kinase II. |
| M7846 | IC 261 | Casein kinase 1 δ (CK1δ) and CK1 ε inhibitor. |
| M7790 | Emodin | Emodin is an anti-SARS-CoV compound that blocks the interaction between the SARS-coronavirus spike protein and angiotensin converting enzyme 2 (ACE2). Emodin inhibited casein kinase 2 (CK2) and 11β-HSD1. Emodin can also induce necrotic apoptosis of glioma U251 cells and inhibit U251 cell proliferation by targeting the TNF/RIPK1/RIPK3 signaling pathway. |
| M7683 | CKI-7 dihydrochloride | CKI-7 is a CK1 inhibitor; also inhibits SGK, S6K1 and MSK1. |
| M6140 | TA 01 | TA-01 potently inhibits CK1ε, CK1δ,and p38α (IC50values are 6.4, 6.8, and 6.7 nM respectively). |
| M5341 | TBB | TBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2)with IC50s of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively). |
| M3153 | TTP 22 | TTP 22 is a high affinity, ATP-competitive casein kinase 2 (CK2) inhibitor with IC50/Ki of 0.1 uM/40 nM. |
| M2610 | D4476 | D4476 is a selective inhibitor of casein kinase 1 (CK1) and TGF-β type-I receptor (ALK5) with IC50 of 0.3 µM and 0.5 µM, respectively. |
| M1903 | PF-4800567 | PF-4800567 is a selective, ATP competitive casein kinase 1ε inhibitor with IC50 values of 32 and 711 nM for CK1ε and CK1δ respectively. |
| M55928 | SJ3149 | SJ3149 is a selective and potent degrader of CK1α protein in vitro and in vivo. |
| M55927 | CK1α degrader-1 | CK1α degrader-1 is an orally active CK1α degrader with a DC50 of 0.105 μM. |
| M45316 | ON 108600 | ON 108600 is an inhibitor of CK2 (Casein Kinase2)/TNIK/DYRK1 with IC50 values of 0.016 μm/0.007 μM, 0.028 μM, 0.05 μM/0.005 μM, and 0.005 μM for DYRK1A/DYRKB, DYRK2, CK2α1/CK2α2, and TNIK, respectively. 0.005 μM. It has anti-tumor activity. |
| M45315 | (R)-DRF053 dihydrochloride | (R)-DRF053 dihydrochloride is a potent inhibitor of casein kinase 1 (CK1), CDK1/cyclin B, and CDK5/p25, with IC50s of 14 nM, 220 nM, and 80 nM, respectively.(R)-DRF053 dihydrochloride prevented the production of CK1-dependent amyloid-β in cellular models. In addition, (R)-DRF053 dihydrochloride prevented the production of CK1-dependent amyloid-β in cell models. |
| M45313 | Casein kinase 1δ-IN-5 | Casein kinase 1δ-IN-5 is a potent and selective protein kinase CK-1δ inhibitor with an IC50 of 47 nM, which has neuroprotective and anti-inflammatory properties in vitro. It has neuroprotective and anti-inflammatory properties in vitro. It can be used in studies related to neurodegenerative diseases. |
| M45312 | CK2-IN-1 | CK2-IN-1 is a CK2 inhibitor with an IC50 value of 150 nM. |
| M45310 | SR-1277 | SR-1277 is a potent, selective and ATP-competitive CK1δ/ε inhibitor with IC50 values of 49 nM and 260 nM, respectively.In addition, SR-1277 inhibits FLT3, CDK4/cyclin D1, CDK6/cyclin D3, and CDK9/cyclin K with IC50 values of 305 nM, 1340 nM, 311 nM, and 109 nM, respectively. 1340 nM, 311 nM and 109 nM, respectively, and can be used in cancer research. |
| M45308 | Casein Kinase II Receptor Peptide | Casein Kinase II Receptor Peptide is a substrate for Casein Kinase II (CK2) with a Km value of 500 µM.CASEIN KINASE II ACTIVITY can be used to determine casein kinase II activity in crude enzyme preparations. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
